Compare Duolingo Inc (DUOL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Merck & Co., Inc. — how do they compare? Duolingo Inc trades at $134.72 (market cap $6.30B), while Merck & Co., Inc. trades at $133.26 (market cap $327.94B). The key difference: Merck & Co., Inc. is far larger — about 52.1× Duolingo Inc's market cap, and Merck & Co., Inc. pays a 2.56% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals.
| DUOL | MRK | |
|---|---|---|
Market Cap | $6.30B | $327.94B |
Sector | Technology | Health |
52-Week High | $369.19 | $132.93 |
52-Week Low | $90.03 | $77.60 |
Enterprise Value | $5.07B | $374.70B |
Dividend Yield | — | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $134.63, down 1.87% amid mixed signals. The stock shows strong fundamentals with impressive revenue growth from $369M in 2022 to $1.04B in 2025 and net income turning positive to $414M. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $134 and resistance at $138. Recent Q2 2026 earnings beat expectations with $0.66 EPS versus $0.604 expected, though Q3 revenue guidance disappointed investors.
The outlook remains cautiously optimistic with robust user growth and profitability metrics, but near-term pressure exists from decelerating booking growth and margin concerns. Analyst consensus is mixed with 30% buy ratings and a $121 price target below current levels. Key risks include monetization challenges despite user growth and increased competitive pressures in the education technology sector.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01B in 2025, and net income reached $18.25B. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples and competitive pressures. Analysts maintain a bullish consensus with a $140.58 price target, suggesting potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
